12 studies found for:    HSPPC-96
Show Display Options
Rank Status Study
1 Active, not recruiting HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
Condition: Brain and Central Nervous System Tumors
Intervention: Biological: HSPPC-96
2 Terminated Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
Condition: Renal Cell Carcinoma
Intervention: Biological: HSPPC-96
3 Active, not recruiting GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: HSPPC-96;   Procedure: conventional surgery
4 Completed Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
Conditions: Non-Small-Cell Lung Carcinoma;   Lung Cancer;   Pulmonary Cancer
Intervention: Biological: HSPPC-96
5 Terminated Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
Conditions: Kidney Cancer;   Renal Cell Carcinoma
Intervention: Biological: HSPPC-96
6 Completed Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Condition: Malignant Melanoma
Intervention: Drug: HSPPC-96 or Oncophage
7 Terminated Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Biological: autologous human tumor-derived HSPPC-96
8 Recruiting Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Biological: HSPPC-96;   Drug: bevacizumab
9 Completed Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
Condition: Renal Cell Carcinoma
Intervention: Drug: autologous human tumor-derived HSPPC-96
10 Completed A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Conditions: Lymphoma, Follicular;   Lymphoma, Small Lymphocytic
Intervention: Drug: autologous human tumor-derived HSPPC-96
11 Completed Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Biological: vitespen
12 Completed Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: vitespen

Indicates status has not been verified in more than two years